Michael Pfeilstocker
Overview
Explore the profile of Michael Pfeilstocker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
2663
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riedl J, Pfeilstocker M, Farr A, Hausler G, Ay C, Fureder W
Ann Hematol
. 2024 Nov;
PMID: 39537992
Pregnant women with paroxysmal nocturnal hemoglobinuria (PNH) are at high risk for life-threatening thromboembolism. Therapy with the complement inhibitor eculizumab is able to mitigate thrombotic risks in PNH and to...
2.
Ravandi F, Dohner H, Wei A, Montesinos P, Pfeilstocker M, Papayannidis C, et al.
Br J Haematol
. 2023 Nov;
204(3):877-886.
PMID: 37952982
In the phase 3 QUAZAR AML-001 trial (NCT01757535) of patients with acute myeloid leukaemia (AML) in remission following intensive chemotherapy (IC) and ineligible for haematopoietic stem cell transplant (HSCT), oral...
3.
Pleyer L, Vaisband M, Drost M, Pfeilstocker M, Stauder R, Heibl S, et al.
Am J Hematol
. 2023 Aug;
98(11):1685-1698.
PMID: 37548390
The current gold standard of response assessment in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) is morphologic complete remission (CR) and CR with...
4.
Valent P, Sadovnik I, Peter B, Ivanov D, Schulenburg A, Hadzijusufovic E, et al.
Expert Rev Hematol
. 2023 Jul;
16(9):659-670.
PMID: 37493441
Introduction: The Vienna Cancer Stem Cell Club (VCSCC) was launched by a group of scientists in Vienna in 2002. Areas Covered: Major aims of the VCSCC are to support research...
5.
Ivanov D, Milosevic Feenstra J, Sadovnik I, Herrmann H, Peter B, Willmann M, et al.
Am J Hematol
. 2023 Feb;
98(5):770-783.
PMID: 36814396
Myeloproliferative neoplasms (MPN) are characterized by uncontrolled expansion of myeloid cells, disease-related mutations in certain driver-genes including JAK2, CALR, and MPL, and a substantial risk to progress to secondary acute...
6.
Leisch M, Pfeilstocker M, Stauder R, Heibl S, Sill H, Girschikofsky M, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626063
Azacitidine is the treatment backbone for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia who are considered unfit for intensive chemotherapy. Detailed reports on adverse events in...
7.
Geissler K, Jager E, Barna A, Gurbisz M, Marschon R, Graf T, et al.
Eur J Haematol
. 2022 Mar;
109(1):50-57.
PMID: 35299281
Background: A multistep pathogenesis of myeloid leukemia including mutations in epigenetic, spliceosome, and signaling genes has been recently demonstrated in a preclinical model but is poorly validated in patients. Methods:...
8.
Heibl S, Stauder R, Pfeilstocker M
Curr Oncol Rep
. 2021 Nov;
23(12):142.
PMID: 34735656
Purpose Of Review: To review available data on the relationship of MDS and aging and to address the question if biological changes of (premature) aging are a prerequisite for the...
9.
Machherndl-Spandl S, Jager E, Barna A, Gurbisz M, Marschon R, Graf T, et al.
Eur J Haematol
. 2021 May;
107(2):265-274.
PMID: 33998054
In older patients with chronic myelomonocytic leukaemia (CMML) and limited life expectancy due to age and or comorbidities, it is particularly important to consider the risk of transformation for individualised...
10.
Urbantat R, Popper V, Menschel E, Pfeilstocker M, Forjan E, Nader A, et al.
Clin Case Rep
. 2021 May;
9(4):1933-1936.
PMID: 33936618
CPX-351, a promising new agent for patients with treatment-related and secondary acute myeloid leukemia can lead to a severe whole-body rash. Although severe side effects are rare, treatment should be...